Jane C. Davies, MBChB MRCP FRCPCH MD FERS (she/her/hers)

Professor
National Heart and Lung Institute, Imperial College London

Poster(s):

• (141) Oxygen Enhanced-MRI (OE-MRI) and Multiple breath washout +/- Short extension (MBW_ShX) as novel functional assessments of CF lung health
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (157) A Randomized Controlled Trial to Determine the Most Sensitive Outcome Measure of Airway Clearance in Cystic Fibrosis
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (163) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and ≥1 F508del allele: 96-week interim results from an open-label extension study
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (166) Measuring adherence to chronic therapies over the first year of treatment with Elexacaftor/Tezacaftor/Ivacaftor in people with Cystic Fibrosis (CF)
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (169) A Phase 4, Fully Decentralized Clinical Trial to Evaluate Physical Activity and Cough Frequency in Patients with Cystic Fibrosis Using Wearable Technology
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (251) Evaluation of Medication Electronic Monitoring Systems (MEMS®) in Adherence Measurement in the real world setting
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (283) Expectations and experiences of adolescents with cystic fibrosis: influence of Elexacaftor/Tezacaftor/Ivacaftor on treatment adherence and identity
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (616) CF Gene Therapy: Moving forward
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (695) Correcting legacy multiple breath nitrogen washout data (MBWN­₂) is not equivalent to collecting new data directly using the corrected software
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET